FDA Recall D-0593-2024

Zydus Pharmaceuticals (USA) Inc · Pennington, NJ

Class III Ongoing 681 days on record

Lower impact — Class III recall — product violates FDA labeling or manufacturing standards but is unlikely to cause adverse health consequences.

Product

Verapamil Hydrochloride Injection, USP 10 mg/4 mL (2.5 mg/mL), 5 x 4 mL Single-Dose Vial per carton, Rx Only, Manufactured by: Zydus Lifesciences Ltd. Vadodara, India, Distributed by: Zydus Pharmaceuticals (USA)Inc., Pennington, NJ 08534, Vial NDC: 70710-1644-1, Carton NDC: 70710-1644-5.

Lot / code: Lot L300269, Exp Date 07/31/2025

Quantity: 8020 vials

Reason for recall

Cross contamination with other products.

Recall record

Recall number: D-0593-2024
Classification: Class III
Status: Ongoing
Voluntary or mandated: Voluntary: Firm initiated
Firm notification: Letter
Distribution: Nationwide in the USA
Recall initiated: 2024-07-02
Classified by FDA Center: 2024-07-10
FDA published: 2024-07-17
Recalling firm: Zydus Pharmaceuticals (USA) Inc
Firm location: Pennington, NJ

Drug identification

Brand name(s): VERAPAMIL HYDROCHLORIDE
Generic name(s): VERAPAMIL HYDROCHLORIDE
Manufacturer(s): Zydus Pharmaceuticals USA Inc.
NDC(s): 70710-1643, 70710-1644
Route(s): INTRAVENOUS

Operational response

Class III recalls are unlikely to cause adverse health consequences but indicate a violation of FDA labeling or manufacturing standards. Pull from active dispensing per your operational policy.

For the official FDA enforcement record, see FDA's Recall Search.

‹ All recalls